Work

The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab

Year: 2025

Type: other

Source: Nature Reviews Clinical Oncology

DOI: 10.1038/s41571-025-01024-y

Authors: Roy S. Herbst, Lieping Chen

Institutions: Yale Cancer Center, Yale University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410123693

Cites: 10

Cited by: 5

Related to: 10